Skip to content

The effect of cabergoline in infertile women on peritoneal endometriosis related dysmenorrhea, chronic pelvic pain and fertility

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-500792-31-00
Enrollment
80
Registered
2022-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis in women with involuntary infertility

Brief summary

The worst Numeric Rating Scale of menstrual pain, weekly pelvic pain and pain during intercourse at baseline, during the treatment, at the end of treatment and at follow up after three natural or ovulation induction cycles and the change of worst NRS at baseline, at the end of treatment and at follow up after three natural or ovulation induction cycles. The number of subjects with reduction of the worst NRS of menstrual pain, weekly pelvic pain and weekly pain during intercourse by ≥30%, ≥50% ja

Interventions

DRUGLume-kapselissa puolitettu yliopiston apteekin Placebo 9 mm tabletti (sis. mikrokiteistä selluloosaa sekä magnesium stearaattia).

Sponsors

Turku University Central Hospital
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
The worst Numeric Rating Scale of menstrual pain, weekly pelvic pain and pain during intercourse at baseline, during the treatment, at the end of treatment and at follow up after three natural or ovulation induction cycles and the change of worst NRS at baseline, at the end of treatment and at follow up after three natural or ovulation induction cycles. The number of subjects with reduction of the worst NRS of menstrual pain, weekly pelvic pain and weekly pain during intercourse by ≥30%, ≥50% ja

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026